The Relationship between Hypomagnesemia, Metformin Therapy and Cardiovascular Disease Complicating Type 2 Diabetes: The Fremantle Diabetes Study

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Peters, Kirsten E ^a   Chubb, S A Paul ^b   Davis, Wendy A ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOMAGNESEMIA; ISCHEMIC HEART DISEASE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MAGNESIUM; MALE; METFORMIN; MIDDLE AGED;

EID: 84883346836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074355     Document Type: Article

References (38)

1. Stutzman FL, Amatuzio DS, (1953) Blood serum magnesium in portal cirrhosis and diabetes mellitus. J Lab Clin Med 41: 215-219.
2. Mather HM, Nisbet JA, Burton GH, Poston GJ, Bland JM, et al. (1979) Hypomagnesaemia in diabetes. Clin Chim Acta 95: 235-242.
3. McBain AM, Brown IR, Menzies DG, Campbell IW, (1988) Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. J Clin Pathol 41: 933-935.
4. Walti MK, Zimmermann MB, Spinas GA, Hurrell RF, (2003) Low plasma magnesium in type 2 diabetes. Swiss Med Wkly 133: 289-292.
5. Bo S, Pisu E, (2008) Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol 19: 50-56.
6. Chaudhary DP, Sharma R, Bansal DD, (2010) Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 134: 119-129.
7. Altura BM, Altura BT, (1995) Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res 41: 347-359.
8. Belin RJ, He K, (2007) Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome. Magnes Res 20: 107-129.
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
10. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, et al. (2012) Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9: e1001204.
11. Lamanna C, Monami M, Marchionni N, Mannucci E, (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13: 221-228.
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
13. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
14. Svare A, (2009) A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea: a case report. Cases J 2: 156.
15. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, et al. (1995) Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 48: 927-940.
16. Dosa MD, Hangan LT, Crauciuc E, Gales C, Nechifor M, (2011) Influence of therapy with metformin on the concentration of certain divalent cations in patients with non-insulin-dependent diabetes mellitus. Biol Trace Elem Res 142: 36-46.
17. Gorelik O, Efrati S, Berman S, Almoznino-Sarafian D, Alon I, et al. (2007) Effect of various clinical variables on total intracellular magnesium in hospitalized normomagnesemic diabetic patients before discharge. Biol Trace Elem Res 120: 102-109.
18. Lameris AL, Monnens LA, Bindels RJ, Hoenderop JG, (2012) Drug-induced alterations in Mg2+ homoeostasis. Clin Sci (Lond) 123: 1-14.
19. Davis TM, Bruce DG, Davis WA, (2013) Cohort profile: The Fremantle Diabetes Study. Int J Epidemiol 42: 412-421.
20. Djurhuus MS, Skott P, Hother-Nielson O, Klitgaard NA, Beck-Nielsen H, (1995) Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinaemic states. Diabet Med 12: 664-669.
21. Jaeger P, Portmann L, Ginalski JM, Jacquet AF, Temler E, et al. (1986) Tubulopathy in nephrolithiasis: consequence rather than cause. Kidney Int 29: 563-571.
22. Elisaf M, Panteli K, Theodorou J, Siamopoulos KC, (1997) Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnes Res 10: 315-320.
23. Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, et al. (2008) A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 32: 766-777.
24. Norman PE, Davis WA, Bruce DG, Davis TM, (2006) Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 29: 575-580.
25. World Health Organisation (2009) Calcium and magnesium in drinking water: Public health significance. Geneva. 39-10 p.
26. Azoulay A, Garzon P, Eisenberg MJ, (2001) Comparison of the mineral content of tap water and bottled waters. J Gen Intern Med 16: 168-175.
27. de Jager J, Kooy A, Lehert P, Wulffele MG, van der Kolk J, et al. (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 340: c2181.
28. Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M, et al. (2004) Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke 35: 22-27.
29. Ohira T, Peacock JM, Iso H, Chambless LE, Rosamond WD, et al. (2009) Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 169: 1437-1444.
30. Larsson SC, Orsini N, Wolk A, (2012) Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr 95: 362-366.
31. Kupetsky-Rincon EA, Uitto J, (2012) Magnesium: Novel applications in cardiovascular disease- A review of the titerature. Ann Nutr Metab 61: 102-110.
32. Reffelmann T, Ittermann T, Dorr M, Volzke H, Reinthaler M, et al. (2011) Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 219: 280-284.
33. Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, et al. (2010) Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J 160: 715-720.
34. Liao F, Folsom AR, Brancati FL, (1998) Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 136: 480-490.
35. Sillars B, Davis WA, Hirsch IB, Davis TM, (2010) Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 12: 757-765.
36. Witkowski M, Hubert J, Mazur A, (2011) Methods of assessment of magnesium status in humans: a systematic review. Magnes Res 24: 163-180.
37. Kroll MH, Elin RJ, (1985) Relationships between magnesium and protein concentrations in serum. Clin Chem 31: 244-246.
38. Mathers TW, Beckstrand RL, (2009) Oral magnesium supplementation in adults with coronary heart disease or coronary heart disease risk. J Am Acad Nurse Pract 21: 651-657.